Monoclonal antibodies against hmgb1
AssigneeThe Feinstein Institute for Medical Research
InventorsWalter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
Life of this patent
Estimating the term…
Abstract
In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
Claims32
1-12. (canceled)
The antibody produced by murine hybridoma 2G7 HMGB1 mAb, deposited as ATCC Accession Number PTA-5432, or an antigen-binding fragment thereof.
(canceled)
(canceled)
(canceled)
22-24. (canceled)
An antibody or antigen-binding fragment thereof wherein said antibody or fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and/or the heavy chain CDRs (CDR1, CDR2 and CDR3) of the 2G7 HMGB1 mAb.
(canceled)
An antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment is selected from the group consisting of:
- a) 2G7 HMGB1 mAb;
- b) an antibody having the epitopic specificity of 2G7 HMGB1 mAb;
- c) an antibody that can compete with 2G7 HMGB1 mAb, for binding to a vertebrate high mobility group box (HMGB) polypeptide;
- and
- d) an antigen-binding fragment of a), b), or c).
(canceled)
37-38. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.